Emergent BioSolutions (EBS) PT Lowered to $64 at Cowen Due to Litigation Loss
Tweet Send to a Friend
Cowen analyst Boris Peaker lowered the price target on Emergent BioSolutions (NYSE: EBS) to $64.00 (from $77.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
